The use of ultralow doses of antibodies to prostate-specific antigen (afala) for long-term treatment of benign prostatic hyperplasia in patients with moderate symptoms rapidly and effectively reduces irritative and obstructive symptoms, significantly decreases residual urine volume, and increases the rate of urination. Afala therapy is indicated for patients with stage I-II benign prostatic hyperplasia of moderately pronounced symptoms.
Similar content being viewed by others
References
L. M. Gorilovskii, Benign Hyperplasia of the Prostate [in Russian], Moscow (1999), pp. 12-20.
V. I. Isaenko and S. A. Stepanenkov, Urgent Problems of Diagnostics and Therapy of Urological Diseases. Proceedings of VI Regional Conference of Urologists in Siberia. Belokurikha (2007), pp. 155-156.
K. V. Savel’eva, S. A. Tarasov, V. n. Pavlov, et al., Proceedings of II National Congress of Therapists. Moscow (2007).
A. V. Sivkov, Benign Hyperplasia of the Prostate [in Russian], Moscow (1999), pp. 91-116.
O. I. Epshtein, M. B. Shtark, A. M. Dygai, et al., Pharmacology of Ultralow Doses of Antibodies to Endogenous Regulators of Functions [in Russian], Moscow (2005).
M. J. Barry, AUA Update Series., 16, 274-279 (1997).
M. Emberton, Eur. Urol. 12, Suppl. 5, 704-709 (2006).
P. Hanno, S. B. Malkowicz, and A. J. Wein, Manual on Clinical Urology [Russian translation], (2006), pp. 274-294.
D. Prezioso, C. Catuogno, P. Galassi, et al., Eur. Urol. 40, Suppl. 1, 9-12 (2001).
A. J. Wein, Prostatic Diseases. Ed. H.Lepor, Philadelpha (1999), pp. 210-231.
Author information
Authors and Affiliations
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 148, Suppl. 1, pp. 57-60, August, 2009
Rights and permissions
About this article
Cite this article
Gudkov, A.V. Experience of Long-Term Afala Treatment in Benign Prostatic Hyperplasia. Bull Exp Biol Med 148, 308 (2009). https://doi.org/10.1007/s10517-009-0695-8
Received:
Published:
DOI: https://doi.org/10.1007/s10517-009-0695-8